WellDoc’s diabetes management system is heading north

With FDA clearance for its prescription-only treatment system and a partnership with electronics giant Samsung, WellDoc is gaining traction in the world of type 2 diabetes treatment.
Now, the Baltimore-based health technology company is heading to the epicenter of diabetes treatment.
WellDoc, which is headquartered in offices near Penn Station, will test its product, BlueStar, on patients with the publicly funded Ontario Telemedicine Network (OTN), in Canada. Given that insulin was discovered in Toronto, WellDoc Chief Data Science Officer Anand Iyer said the province usually likes to be on the cutting edge when it comes to treating the disease, in which the body does not use insulin properly.
“OTN recognized that this solution is something that can accelerate how they manage diabetes,” Iyer said.

It will be a great learning opportunity for not just us but the entire industry.

BlueStar is a smartphone-based treatment that is designed to help type 2 diabetes patients manage their medical needs and lifestyle during all of the times when they aren’t under clinical care.
Along with medication and glucose, the app’s integration with Samsung’s S Health also monitors more general lifestyle concerns like eating habits, sleep and physical activity that also factor into a diabetes patient’s health.
In Ontario, BlueStar will be prescribed to 300 diabetes patients.
Given the growth of telemedicine and health tracking apps in general, the idea is to show that the two systems can work together to improve type 2 diabetes treatment, and look at whether it will be an effective treatment for the 1.2 million diabetics living in Ontario.
“It will be a great learning opportunity for not just us but the entire industry,” Iyer said.